Cancer
Researchers at Teclison Inc. have made a significant breakthrough in cancer treatment with a new patent that discloses a method of enhancing an immune response against solid tumors. The method combines the use of hypoxia-activated bioreductive agents (HABAs) with immune checkpoint inhibitors to stimulate the immune system to attack cancer
Cancer
Researchers at the University of Texas MD Anderson Cancer Center have made a groundbreaking discovery in the field of life sciences, demonstrating that increasing tumor oxygenation can promote T cell infiltration and tumor control by immune checkpoint blockade. This breakthrough has significant implications for the development of new cancer treatments.
Cancer
A recent study published in the Blood Cancer Journal has shed light on the importance of immune reconstitution in vaccine responses post-CAR T therapy for patients with hematological malignancies. Researchers at Memorial Sloan-Kettering Cancer Center conducted a single-center, retrospective study analyzing vaccine responses in 73 patients who received post-CAR T
Cancer
Researchers from the Fred Hutchinson Cancer Research Center in Seattle, Washington, have found that dysregulation of the bone marrow niche in multiple myeloma alters the composition and state of resident immune cells, potentially impeding antitumor immunity. This study, published in the Blood Journal, investigated the extent of T-cell exhaustion in
Cancer
A new study has shed light on the association between chimeric antigen receptor (CAR) T-cell therapy and sarcopenia, a hallmark of cancer cachexia. Researchers at the H. Lee Moffitt Cancer Center and Research Institute discovered that patients with baseline sarcopenia had poorer tolerance and reduced survival after CAR-T cell therapy.
Cancer
Researchers at Dana-Farber Cancer Institute presented findings at the American Society for Transplantation and Cellular Therapy (ASTCT) 80/20 Workshop in June 2023, where a consensus emerged on the need for simplification and streamlining of existing CAR-T REMS programs. The experts recommended replacing manufacturer-created training with treatment center-administered programs, reporting
Cancer
Cue Biopharma, a clinical-stage biopharmaceutical company, has reported a significant clinical update on its most advanced asset, CUE-101, which is showing promise in treating HPV-induced cancers. The company announced an additional complete response in a patient with recurrent metastatic HPV+ head and neck squamous cell carcinoma (HNSCC) treated with CUE-101
Cancer
Researchers at Indiana University School of Medicine have discovered a potential new approach to combat acute myeloid leukemia, a fatal and aggressive form of blood cancer, by targeting both cancer cells and their protective environment. The study's findings, published in Nature Communications, focus on the role of leukemia
Cancer
Researchers at the University of Texas MD Anderson Cancer Center conducted a retrospective study of 66 patients who underwent CAR-T therapy to examine the association between pre-CAR-T pulmonary function testing (PFT) and subsequent complications. The study found that higher lung function scores correlated with increased risk of cytokine release syndrome
Cancer
Research by a team of scientists at the National Cancer Institute (NCI) has uncovered new molecular mechanisms for regulating MHC class II (MHC-II) expression in antigen-presenting cells (APCs). The study reveals that the E3 ubiquitin ligase March-I controls the turnover of surface pMHC-II on APCs, while the protein CD83 suppresses
Cancer
A peer-reviewed study published in the journal Theranostics reveals that a secreted, truncated form of the Clever-1 receptor (sClever-1) acts as an immunosuppressive mediator in cancer, impairing T-cell responses and contributing to resistance to anti-programmed cell death protein-1 (PD-1) immunotherapies. Researchers found that high levels of sClever-1 were associated with
Cancer
Researchers from Fujian Medical University have discovered a promising approach to improving the effectiveness of chimeric antigen receptor (CAR) T-cell therapy for solid tumors. The study, published in the Journal of Translational Medicine, suggests that biomimic nanoenzymes can be used to enhance CAR-T cell infiltration and efficacy by addressing vascular
